Results of adjuvant BCG immunotherapy in malignant melanoma.
98 stage I melanoma patients and 16 stage II melanoma patients were included in this BCG immunotherapy trial. The postoperative treatment was performed by a high dose of BCG (Jena strain) administered by scarification with an intensive schedule. Compared to a similar historical control group treated by surgery alone (69 cases), the stage I melanoma patients showed a significantly improved recurrence rate and survival rate. In stage II melanoma patients we cannot prove any therapeutical effect of BCG therapy.
D001500:BCG Vaccine / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000601:surgery / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011379:Prognosis; D012878:Skin Neoplasms / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine